Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eli Lilly Ropes In Lupin For A Big Push For Its Insulin Brands In India

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - As Pfizer Inc. warms up for an entry into the rapidly growing Indian insulin market, Eli Lilly & Co., which is already established in the Indian market, is looking to strengthen its franchise via a strategic collaboration with Lupin Ltd. - an Indian company making significant strides in the anti-diabetes, cardiology, nephrology and respiratory segments
Advertisement

Related Content

Emerging Markets Slowdown Trips Up Lilly’s 2014 Revenue Estimates
As India’s Diabetes Market Grows, Eli Lilly Brings In A New Leader
Eli Lilly, Boehringer Ingelheim Combine Might To Push Brands As India's Diabetes Market Expands
Seeking Broad Intervention In India, Eli Lilly Goes To Roots To Check Non-communicable Diseases
Seeking Broad Intervention In India, Eli Lilly Goes To Roots To Check Non-communicable Diseases
Lupin Categorically Denies Sell-off Talks Amid Speculation Of $1 Billion Valuation For India Business
Armed With A Range Of Insulins, Pfizer Is Weeks Away From Its First Biosimilars Rollout In India - BIO 2011 Conference
India's Sales Rankings Shuffle As IMS Health Widens Audit To Hospitals And Doctors
Eli Lilly Global External R&D VP Robert Armstrong On Attracting Indian Innovators As Partners: An Interview With PharmAsia News
Eli Lilly Global External R&D VP Robert Armstrong On Attracting Indian Innovators As Partners: An Interview With PharmAsia News
Advertisement
UsernamePublicRestriction

Register

SC078686

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel